Loading peptide…
PeptideChat is for educational and research purposes only. Nothing on this site constitutes medical advice. Peptides are sold as research chemicals only and are not intended for human use. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. PeptideChat is an independent educational resource — not a pharmacy, compounding, or 503A/503B outsourcing facility — and does not sell products or provide medical advice.
Also known as: Liraglutide, Victoza, Saxenda
Liraglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management. Its fatty-acid modification gives it a once-daily dosing profile.
Sign in to rate this peptide.
Liraglutide is a long-acting analog of glucagon-like peptide-1 (GLP-1) with a C16 fatty-acid chain that promotes albumin binding and resistance to DPP-4 degradation. It activates the GLP-1 receptor on pancreatic beta cells, enhancing glucose-dependent insulin secretion while suppressing inappropriate glucagon release. Centrally, it acts on hypothalamic appetite circuits to increase satiety and reduce food intake, and it slows gastric emptying. Together these actions improve glycemic control and promote weight loss.